Calidi Biotherapeutics announced a partnership with Avance Clinical to rapidly initiate clinical trials in Australia, leveraging Avance's experience obtaining regulatory approvals and starting trials there. The deal could accelerate Calidi's clinical timeline and reduce execution risk for near-term development milestones, but lacks financial, timeline or design details and is unlikely to move the stock materially without further updates.
Calidi Biotherapeutics announced a partnership with Avance Clinical to rapidly initiate clinical trials in Australia, leveraging Avance's experience obtaining regulatory approvals and starting trials there. The deal could accelerate Calidi's clinical timeline and reduce execution risk for near-term development milestones, but lacks financial, timeline or design details and is unlikely to move the stock materially without further updates.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
